| 名稱 | KIF5B（E15）-RET（E12）-Short/BaF3 |
| 型號 | CBP73205 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | KIF5B（E15）-RET（E12）-Short/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 有關(guān)細(xì)胞株生長要考慮的因素
- RNA-Fusion Cocktail再升級
- 談?wù)勀[瘤細(xì)胞為何對抑制生長信號不敏感
- 降糖&減肥明星靶點(diǎn)：GLP1R/GIPR/GCGR
- 【產(chǎn)品推介】胰高血糖素受體藥物細(xì)胞篩選模型
- NK2R細(xì)胞篩選模型
- VKORC1基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- NIPT標(biāo)準(zhǔn)品-助力無創(chuàng)產(chǎn)前檢測
- 大腦中新發(fā)現(xiàn)的一種淋巴細(xì)胞，能夠清除大腦廢物
- IHC第三方質(zhì)控品——病理質(zhì)控基石，精準(zhǔn)診斷起點(diǎn)
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73205KIF5B（E15）-RET（E12）-Short/BaF3
- 詳細(xì)內(nèi)容
| CBP73205 | |
| I. Introduction | |
Cell Line Name： | KIF5B(E15)-RET(E12)-Short/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies. | |
| III. Representative Data | |
1. WB of KIF5B-RET (K15, R12S)/BaF3
| |
2. Sanger of KIF5B-RET (K15, R12S)/BaF3
| |
3. Anti-proliferation assay
Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (s) Cells (C6). | |
